Biogen Inc. (BIIB): Price and Financial Metrics


Biogen Inc. (BIIB): $225.21

6.27 (+2.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BIIB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

BIIB POWR Grades


  • BIIB scores best on the Value dimension, with a Value rank ahead of 96.76% of US stocks.
  • The strongest trend for BIIB is in Growth, which has been heading up over the past 169 days.
  • BIIB's current lowest rank is in the Momentum metric (where it is better than 9.25% of US stocks).

BIIB Stock Summary

  • Biogen Inc's market capitalization of $32,160,690,365 is ahead of 91.75% of US-listed equities.
  • Biogen Inc's stock had its IPO on September 17, 1991, making it an older stock than 82.74% of US equities in our set.
  • As for revenue growth, note that BIIB's revenue has grown -22.17% over the past 12 months; that beats the revenue growth of just 8.33% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biogen Inc are KEYS, ZBRA, NOK, GRMN, and CMI.
  • BIIB's SEC filings can be seen here. And to visit Biogen Inc's official web site, go to www.biogen.com.

BIIB Valuation Summary

  • BIIB's price/earnings ratio is 26.3; this is 27.95% lower than that of the median Healthcare stock.
  • BIIB's EV/EBIT ratio has moved down 38.1 over the prior 243 months.
  • Over the past 243 months, BIIB's price/sales ratio has gone down 36.1.

Below are key valuation metrics over time for BIIB.

Stock Date P/S P/B P/E EV/EBIT
BIIB 2021-08-31 4.3 4.7 26.3 31.2
BIIB 2021-08-30 4.4 4.8 26.8 31.7
BIIB 2021-08-27 4.4 4.8 26.7 31.6
BIIB 2021-08-26 4.4 4.7 26.6 31.5
BIIB 2021-08-25 4.4 4.8 26.6 31.5
BIIB 2021-08-24 4.5 4.8 27.1 32.1

BIIB Growth Metrics

    Its 4 year revenue growth rate is now at 31.88%.
  • Its year over year revenue growth rate is now at -12.61%.
  • The 4 year net income to common stockholders growth rate now stands at 59.09%.
Over the past 33 months, BIIB's revenue has gone down $2,352,400,000.

The table below shows BIIB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 11,100.5 2,434.5 1,545.8
2021-06-30 11,697.7 2,810.3 1,918.1
2021-03-31 12,604.3 3,531.5 3,011.7
2020-12-31 13,444.6 4,229.8 4,000.6
2020-09-30 14,263.3 6,557.1 5,082.4
2020-06-30 14,487.3 7,070.9 5,926.8

BIIB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BIIB has a Quality Grade of B, ranking ahead of 87.69% of graded US stocks.
  • BIIB's asset turnover comes in at 0.459 -- ranking 97th of 680 Pharmaceutical Products stocks.
  • ZSAN, ARMP, and HGEN are the stocks whose asset turnover ratios are most correlated with BIIB.

The table below shows BIIB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.459 0.825 0.064
2021-06-30 0.478 0.839 0.098
2021-03-31 0.510 0.855 0.206
2020-12-31 0.531 0.866 0.283
2020-09-30 0.550 0.876 0.369
2020-06-30 0.545 0.880 0.415

BIIB Price Target

For more insight on analysts targets of BIIB, see our BIIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $417.00 Average Broker Recommendation 1.64 (Moderate Buy)

BIIB Stock Price Chart Interactive Chart >

Price chart for BIIB

BIIB Price/Volume Stats

Current price $225.21 52-week high $468.55
Prev. close $218.94 52-week low $214.88
Day low $217.92 Volume 1,318,537
Day high $225.23 Avg. volume 1,951,040
50-day MA $235.90 Dividend yield N/A
200-day MA $291.08 Market Cap 33.08B

Biogen Inc. (BIIB) Company Bio


Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. The company was founded in 1985 and is based in Cambridge, Massachusetts.


BIIB Latest News Stream


Event/Time News Detail
Loading, please wait...

BIIB Latest Social Stream


Loading social stream, please wait...

View Full BIIB Social Stream

Latest BIIB News From Around the Web

Below are the latest news stories about Biogen Inc that investors may wish to consider to help them evaluate BIIB as an investment opportunity.

Biogen to sell stake in Samsung Bioepis for more than $2 billion

Biogen (NASDAQ:BIIB) announced an agreement with Samsung BioLogics whereby the company will sell its stake in the Samsung Bioepis joint venture to the South Korean partner, for up to $2.3B. In 2012, Biogen and Samsung BioLogics established Samsung Bioepis to focus on biosimilar therapeutics across clinical areas such as immunology, oncology,...

Seeking Alpha | January 28, 2022

Cambiar Investors Llc Buys iShares MSCI EAFE ETF, Barclays PLC, Constellation Brands Inc, Sells ...

Denver, CO, based Investment company Cambiar Investors Llc (Current Portfolio) buys iShares MSCI EAFE ETF, Barclays PLC, Constellation Brands Inc, Activision Blizzard Inc, iShares Russell 1000 Value ETF, sells Itau Unibanco Holding SA, ASML Holding NV, Biogen Inc, 3M Co, Banco Santander SA during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cambiar Investors Llc.

Yahoo | January 27, 2022

Nbt Bank N A Buys Vanguard High Dividend Yield Indx ETF, Dow Inc, Global X U.S. ...

Investment company Nbt Bank N A (Current Portfolio) buys Vanguard High Dividend Yield Indx ETF, Dow Inc, Global X U.S.

Yahoo | January 27, 2022

Biogen lays out plans for confirmatory study of Alzheimer's drug

The Cambridge drugmaker has laid out ambitious plans for its FDA-required confirmatory trial of its Alzheimer's drug, Aduhelm. The plans include a diverse patient cohort, as well as new endpoints designed to rate patients' levels of cognitive impairment.

Yahoo | January 27, 2022

Earnings Preview: Biogen Inc. (BIIB) Q4 Earnings Expected to Decline

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | January 27, 2022

Read More 'BIIB' Stories Here

BIIB Price Returns

1-mo -12.81%
3-mo -15.55%
6-mo -31.07%
1-year -15.93%
3-year -32.67%
5-year -12.12%
YTD -6.13%
2021 -2.02%
2020 -17.48%
2019 -1.39%
2018 -5.54%
2017 21.96%

Continue Researching BIIB

Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:

Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7725 seconds.